Identifying Key Hematological and Biochemical Indicators of Disease Severity in COVID-19 and Non-COVID-19 Patients
Diagnostics · 29.05.2025 · 15 (11) · 1374
DOI: 10.3390/diagnostics15111374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 29.05.2025. Verfasst von Soo-Kyung Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Ewha Womans University College of Medicine, Seoul 07985, Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sysmex Corporation.
Abstract (Originalsprache)
Background
This study investigated hematological and biochemical parameters, including cell population data (CPD), to evaluate their association with severity in COVID-19 and non-COVID-19 patients. Identifying these parameters could aid in disease monitoring and clinical decision-making.
Methods
A retrospective analysis of 8401 patients, including 603 COVID-19 cases and 7546 non-COVID-19 cases, were conducted. Complete blood count (CBC) and routine chemistry results obtained near the time of real-time polymerase chain reaction testing were analyzed to assess their associations with disease severity. A matched cohort analysis was performed to adjust for potential confounding factors, such as age and sex.
Results
COVID-19 patients with elevated neutrophil side fluorescence light (NE-SFL), platelet-to-lymphocyte ratio (PLR), glucose, and aspartate aminotransferase (AST), along with decreased plateletcrit, were more likely to experience severe outcomes, such as hospitalization or death. In addition, decreased hemoglobin, lymphocyte side scatter (LY-SSC), and albumin, as well as increased leukocyte and monocyte side scatter (MO-SSC), were associated with a greater severity, regardless of COVID-19 status.
Conclusions
We identified hematologic and chemical assay biomarkers that correlate with severe COVID-19. These findings may provide important information regarding the disease progression and clinical management. Incorporating these biomarkers into clinical decision support systems could facilitate personalized treatment strategies, optimize resource allocation, and enable real-time severity stratification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Ewha Womans University College of Medicine, Seoul 07985, Republic of Korea.
- Division of Data Science, College of Software Digital Healthcare Convergence, Yonsei University, Wonju 26493, Republic of Korea.
- Department of Laboratory Medicine, Wonju College of Medicine, Yonsei University, Wonju 26426, Republic of Korea.
- Department of Laboratory Medicine, Kangwon National University School of Medicine, Chuncheon 24341, Republic of Korea.
ORCID-Profile: Soo-Kyung Kim, Jong-Han Lee, Sook Won Ryu
Förderung
- Sysmex Corporation
Zitieren
APA
Kim, S. K., Pak, D., Lee, J. H., & Ryu, S. W. (2025). Identifying Key Hematological and Biochemical Indicators of Disease Severity in COVID-19 and Non-COVID-19 Patients. Diagnostics, 15(11), 1374. https://doi.org/10.3390/diagnostics15111374
Vancouver
Kim SK, Pak D, Lee JH, Ryu SW. Identifying Key Hematological and Biochemical Indicators of Disease Severity in COVID-19 and Non-COVID-19 Patients. Diagnostics. 2025;15(11):1374. doi:10.3390/diagnostics15111374
BibTeX
@article{Kim2025,
author = {Kim, Soo-Kyung and Pak, Daewoo and Lee, Jong-Han and Ryu, Sook Won},
title = {Identifying Key Hematological and Biochemical Indicators of Disease Severity in COVID-19 and Non-COVID-19 Patients},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {11},
pages = {1374},
doi = {10.3390/diagnostics15111374}
}
EUVIMED